Analysts forecast that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report ($1.29) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Five Prime Therapeutics’ earnings. The highest EPS estimate is ($1.04) and the lowest is ($1.51). Five Prime Therapeutics posted earnings per share of ($0.73) in the same quarter last year, which suggests a negative year-over-year growth rate of 76.7%. The business is expected to issue its next quarterly earnings report after the market closes on Tuesday, February 27th.
On average, analysts expect that Five Prime Therapeutics will report full year earnings of ($5.56) per share for the current financial year, with EPS estimates ranging from ($5.84) to ($5.38). For the next year, analysts expect that the firm will post earnings of ($5.00) per share, with EPS estimates ranging from ($6.65) to ($3.23). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Five Prime Therapeutics.
A number of research analysts recently issued reports on FPRX shares. Royal Bank of Canada restated a “buy” rating and set a $41.00 price objective on shares of Five Prime Therapeutics in a research report on Wednesday, October 25th. BidaskClub upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Zacks Investment Research raised Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. BMO Capital Markets lifted their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an “outperform” rating in a research note on Tuesday, November 7th. Finally, ValuEngine downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Three analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.00.
A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its stake in Five Prime Therapeutics by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock valued at $646,000 after acquiring an additional 397 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in Five Prime Therapeutics by 3.0% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 494 shares in the last quarter. Voya Investment Management LLC raised its stake in Five Prime Therapeutics by 9.5% during the 2nd quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock valued at $379,000 after acquiring an additional 1,097 shares in the last quarter. Alps Advisors Inc. raised its stake in Five Prime Therapeutics by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 28,330 shares of the biotechnology company’s stock valued at $1,159,000 after acquiring an additional 2,364 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in Five Prime Therapeutics by 8.5% during the 3rd quarter. New York State Common Retirement Fund now owns 30,600 shares of the biotechnology company’s stock valued at $1,252,000 after acquiring an additional 2,400 shares in the last quarter. 73.98% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Five Prime Therapeutics Inc (FPRX) Expected to Post Earnings of -$1.29 Per Share” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://stocknewstimes.com/2018/03/14/five-prime-therapeutics-inc-fprx-expected-to-post-earnings-of-1-29-per-share.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.